Headless WordPress - PROD

Mechanistic insights reveal opportunities for targeting active absorption pathways in refractory hyperphosphatemia

https://sharecareprofessional.top/hcp/nephrology/intestinal-phosphate-transport-beyond-binder-paradigms

Intestinal phosphate transport: Moving beyond binder-based paradigms

Evidence-based frameworks for identifying candidates for alternative phosphate management strategies

https://sharecareprofessional.top/hcp/nephrology/patient-selection-treatment-optimization-novel-mechanisms

Patient selection and treatment optimization: Integrating novel mechanisms into clinical practice

Advancing therapeutic strategies through mechanistic insight and real-world treatment considerations

https://sharecareprofessional.top/hcp/nephrology/emerging-hyperphosphatemia-management-physiology-therapeutic-innovation

Emerging directions in hyperphosphatemia management: Bridging physiologic complexity and therapeutic innovation

Real-world evidence highlights the gap between guideline recommendations and achieved phosphate control

https://sharecareprofessional.top/hcp/nephrology/clinical-challenges-persistent-hyperphosphatemia-adherence-outcomes-unmet-needs

Clinical challenges in persistent hyperphosphatemia: Adherence

Clinical challenges in persistent hyperphosphatemia: Adherence, outcomes, and unmet needs

Featured Content

Dx Dialogues: Hyperphosphatemia

Nephrologist and obesity medicine specialist Sean Hashmi, MD, MS, FASN, explores the use of transport inhibitors for CKD and hyperphosphatemia, patient selection for novel therapies, and emerging advances in chronic kidney disease treatment.